Allergy Therapeutics (AGY): AIM delisting and re-registration

This situation live

AGY Allergy Therapeutics

£253m · 1.5p · −59% since the first step

3 Nov 2026 · Proposed; circular and AGM notice to follow · +0% since Any Cancellation would require the approval of not less than 75 percent of votes cast by shareholders, in accordance with Rule 41 of the AIM Rules for Companies.

Delisting / take-private

AIM delisting and re-registration

Proposed; circular and AGM notice to follow

Next: Shareholder vote on special resolutions at the AGM

Every step · 1

3 Nov 2026 Proposed; circular and AGM notice to follow – Any Cancellation would require the approval of not less than 75 percent of votes cast by shareholders, in accordance with Rule 41 of the AIM Rules for Companies. ↗

What is happening

Allergy Therapeutics: AIM delisting and re-registration – Proposed; circular and AGM notice to follow. ['Proposed; circular and AGM notice to follow']

In short: On 3 November 2026 the Board announced it will propose cancelling AIM admission and re-registering as a private company, citing a market cap that undervalues the company, limited free float and liquidity, and AIM costs. Both major shareholders support it. Needs 75% of votes cast at the AGM; a circular follows.
Announced: 3 Nov 2026 · Proposed; circular and AGM notice to follow
Approval needed: Special Resolutions at the AGM; not less than 75% of votes cast (AIM Rule 41)
Board view: Unanimously concluded Cancellation and Re-registration is in the best interest of the Company and shareholders
Major shareholders: Both major shareholders support it and intend to vote in favour
Last trading day: About five business days after the Special Resolutions pass at the AGM
Dealing after: Company intends to offer a matched bargain facility
Timetable: Circular and AGM notice to follow 'in due course'; no dates given

What comes next

Shareholder vote on special resolutions at the AGM.

Briefing Pro

New to Allergy Therapeutics? Get up to speed in 2 minutes.

What it does, how it got here, what management promised and delivered – written from its own announcements.

Get the AGY briefing →

From the company's own announcements. Not investment advice.

Also at Allergy Therapeutics 1 open

Project milestonesVLP Peanut PROTECT trial – Now a primary listing, still no timetable Dilutive fundraisePotential equity raise – No raise; debt funded, cash £24.2m · closed Insider conviction1 director buying – £2,479k in 1 buy · closed Stake building towards controlZQ Capital Management Limited towards control – 60.31% (from 25.58%) · closed Allergy Therapeutics – company page →